Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Revumenib Displays Activity in Relapsed/Refractory KMT2A+ Acute Leukemias

December 8th 2024

Revumenib demonstrated meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia.

AdAPT-001 Gets FDA Fast Track Designation in Recurrent/Refractory Soft Tissue Sarcoma

December 6th 2024

AdAPT-001 plus nivolumab or atezolizumab has received fast track designation from the FDA in recurrent/refractory soft tissue sarcoma.

FDA Grants Priority Review to Durvalumab for Muscle-Invasive Bladder Cancer

December 6th 2024

The FDA has granted priority review to the sBLA seeking the approval of durvalumab for muscle-invasive bladder cancer.

ALL Treatment Paradigm Displays Significant Gains as NCCN Guidelines Evolve

December 6th 2024

The therapeutic arsenal for patients with ALL in the first line and beyond is expanding beyond traditional approaches, enabling better outcomes for patients.

PD-1 Inhibitors Make Impact in Merkel Cell Carcinoma, But Unmet Needs Persist

December 3rd 2024

PD-1 Inhibitors have proved efficacious in approximately half of patients with metastatic MCC, and ongoing research in the field is looking at combination therapies.

Vice Chair of the B-Cell Lymphomas NCCN Guidelines Maps Critical Changes From 2024

December 2nd 2024

Leo I. Gordon, MD, parses major changes to the 2024 NCCN guidelines for the treatment of patients with MCL, MZL, and follicular lymphoma.

The Addition of Asciminib and Removal of Omacetaxine Mark Notable CML NCCN Guideline Updates

December 1st 2024

Neil P. Shah, MD, PhD, highlights key recent changes to the CML NCCN guidelines and details anticipated data for 2025.

Osimertinib as Consolidation Therapy for Unresectable Locally Advanced Disease Is Most Impactful Addition to 2024 NSCLC NCCN Guidelines

November 29th 2024

Jonathan Wesley Riess, MD, MS, and Megan E. Daly, MD, provide radiation and medical oncology perspectives on NCCN guideline updates in lung cancer.

Obe-Cel Approval Expands CAR T-Cell Therapy Options in Relapsed/Refractory ALL

November 29th 2024

Hematologic oncologists offer their perspective on the current and potential future standing of CAR T-cell therapies in the relapsed/refractory ALL treatment landscape.

Targeting IL-12 Safely With Intraperitoneal Therapy Represents Key Step Forward in Ovarian Cancer

November 28th 2024

Premal Thaker, MD, MS, discusses considerations when targeting IL-12 in ovarian cancer and how IMNN-001 has shown the potential to do so.

Targeted Therapies Represent Core 2024 NCCN GI Cancer Guideline Advancements

November 27th 2024

Alan P. Venook, MD, describes challenges implementing NCCN guidelines into practice in rectal, colon, and biliary tract cancers, and advancements from 2024.

EC Approves Frontline Tislelizumab Plus Chemo for Advanced ESCC and Gastric/GEJ Cancer

November 27th 2024

Tislelizumab plus chemotherapy has been approved in Europe for first-line advanced ESCC and gastric/GEJ adenocarcinoma.

Adjuvant Ribociclib Wins EU Approval for HR+/HER2– Early Breast Cancer

November 27th 2024

Adjuvant ribociclib plus endocrine therapy was approved in Europe for HR-positive/HER2-negative early breast cancer at high risk of recurrence.

Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC

November 27th 2024

China’s NMPA has approved sacituzumab tirumotecan for pretreated unresectable locally advanced or metastatic triple-negative breast cancer.

MAXILUS Study Looks to Further Elucidate the Role of Luspatercept in MDS

November 26th 2024

The MAXILUS study will evaluate the maximum approved dose of luspatercept in lower-risk myelodysplastic syndrome.

Obe-Cel Stands Out in ALL as the Sole FDA-Approved CAR T-Cell Therapy Given Via Split Dosing

November 26th 2024

Elias Jabbour, MD, highlights the significance of obecabtagene autoleucel’s approval for patients with B-cell precursor ALL and data from the FELIX trial.

Education, Telehealth, and Access Initiatives Aim to Improve Cancer Care for Veterans

November 26th 2024

Manali I. Patel, MD, MPH, MS, details several interventions developed to better serve veterans with cancer who are experiencing economic, social, and geographic barriers to care.

Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation

November 25th 2024

Alan P. Venook, MD, highlights notable NCCN guideline updates in HCC, considerations for implementing the changes in the clinic, and next steps in HCC.

Tovorafenib Leads to Durable Off-Treatment Responses in Pediatric BRAF-Altered R/R Low-Grade Glioma

November 23rd 2024

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

NanO2 Plus Radiation/Temozolomide Is Under Exploration in Newly Diagnosed Glioblastoma

November 23rd 2024

Early safety findings from the phase 2b RESTORE study (NCT03862430) of NanO2 plus radiation and temozolomide in newly diagnosed glioblastoma were shared.